Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / LPCN - Lipocine enters settlement and license agreement with Clarus Therapeutics


LPCN - Lipocine enters settlement and license agreement with Clarus Therapeutics

designer491/iStock via Getty Images Lipocine ([[LPCN]] -2.3%) has entered into a global settlement and license agreement with Clarus Therapeutics to resolve outstanding claims in an on-going intellectual property dispute. Terms of the settlement were not disclosed. Last month, Cantor Fitzgerald initiated coverage of Lipocine with an overweight rating and a price target that equated to 121% upside.

For further details see:

Lipocine enters settlement and license agreement with Clarus Therapeutics
Stock Information

Company Name: Lipocine Inc.
Stock Symbol: LPCN
Market: NASDAQ
Website: lipocine.com

Menu

LPCN LPCN Quote LPCN Short LPCN News LPCN Articles LPCN Message Board
Get LPCN Alerts

News, Short Squeeze, Breakout and More Instantly...